Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F O'Brien

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Advances in Neurology|September 29, 1998
Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patientsP A Cullis, C F O'Brien, D D Truong, et al.
Clinical Neuropharmacology|May 10, 2000
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesiaR A Hauser, J Friedlander, T A Zesiewicz, et al.
Neurology|May 1, 1996
Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trialD M Simpson, D N Alexander, C F O'Brien, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 5, 1998
Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experienceR M Trosch, J H Friedman, M C Lannon, et al.
Neurology|August 1, 1997
Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study GroupC H Adler, K D Sethi, R A Hauser, et al.
Archives of Neurology|September 18, 1998
Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study GroupK D Sethi, C F O'Brien, J P Hammerstad, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 1, 1997
A controlled trial of fluoxetine in nondepressed patients with Huntington's diseaseP G Como, A J Rubin, C F O'Brien, et al.
Transplantation Proceedings|February 1, 1995
Lack of a detectable systemic humoral/cellular allogeneic response in human and nonhuman primate recipients of embryonic mesencephalic allografts for the therapy of Parkinson's diseaseA A Ansari, A Mayne, C R Freed, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Advances in Neurology|September 29, 1998
Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patientsP A Cullis, C F O'Brien, D D Truong, et al.
Clinical Neuropharmacology|May 10, 2000
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesiaR A Hauser, J Friedlander, T A Zesiewicz, et al.
Neurology|May 1, 1996
Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trialD M Simpson, D N Alexander, C F O'Brien, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 5, 1998
Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experienceR M Trosch, J H Friedman, M C Lannon, et al.
Neurology|August 1, 1997
Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study GroupC H Adler, K D Sethi, R A Hauser, et al.
Archives of Neurology|September 18, 1998
Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study GroupK D Sethi, C F O'Brien, J P Hammerstad, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 1, 1997
A controlled trial of fluoxetine in nondepressed patients with Huntington's diseaseP G Como, A J Rubin, C F O'Brien, et al.
Transplantation Proceedings|February 1, 1995
Lack of a detectable systemic humoral/cellular allogeneic response in human and nonhuman primate recipients of embryonic mesencephalic allografts for the therapy of Parkinson's diseaseA A Ansari, A Mayne, C R Freed, et al.
Pageof 2